Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07109219 · ClinicalTrials.gov registry record · Phase 1
Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
A Phase 1 study of B-cell Acute Lymphoblastic Leukemia (B-ALL), sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 83
- Enrollment target
- 20
- Study locations
NCT07109219: Recruiting Phase 1 study of B-cell Acute Lymphoblastic Leukemia (B-ALL), sponsored by AstraZeneca.
NCT07109219 is a Phase 1 study of B-cell Acute Lymphoblastic Leukemia (B-ALL) that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 83 participants, below the 119-participant average among 6 other B-cell Acute Lymphoblastic Leukemia (B-ALL) trials with a reported enrollment target (30% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07109219, a Phase 1 study of B-cell Acute Lymphoblastic Leukemia (B-ALL), is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 83 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study is intended to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AZD4512 in patients with relapsed/refractory B-Cell acute lymphoblastic leukemia (r/r B-ALL).
Primary Outcome
DLTs are dose-limiting toxicities as defined in the study protocol.
Conditions Studied
Interventions
- COMBINATION_PRODUCT AZD4512 monotherapy
Study Locations (20)
Other
- Research Site - Melbourne
- Research Site - Guangzhou
- Research Site - Tianjin
- Research Site - Bunkyō City
- Research Site - Chūōku
- Research Site - Seoul
- Research Site - Seoul
- Research Site - Seoul
- Research Site - Seoul
- Research Site - Badalona(Barcelona)
- Research Site - Barcelona
- Research Site - Salamanca
California
- Research Site - Duarte
Florida
- Research Site - Jacksonville
Illinois
- Research Site - Chicago
Iowa
- Research Site - Iowa City
Tennessee
- Research Site - Franklin
Texas
- Research Site - Houston
British Columbia
- Research Site - Vancouver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2025-11-12 |
| Est. Completion | 2028-07-03 |
| Phase | Phase 1 |
What NCT07109219 shows while recruiting
NCT07109219 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 83 participants, a relatively small participant target, below the 119-participant average among 6 other B-cell Acute Lymphoblastic Leukemia (B-ALL) trials with a reported enrollment target (30% lower).
The record links to 1 condition, with B-cell Acute Lymphoblastic Leukemia (B-ALL) appearing as the primary indexed condition, and to 1 intervention - of which AZD4512 monotherapy is the first listed.
NCT07109219 names 20 study sites across 9 states, led by Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT07109219 about?
NCT07109219 is a clinical study titled "Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia". The study is intended to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AZD4512 in patients with relapsed/refractory B-Cell acute lymphoblastic leukemia (r/r B-ALL).
What is the current status of trial NCT07109219?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 83 participants. The study started on 2025-11-12. Estimated completion is 2028-07-03.
What conditions does trial NCT07109219 study?
This clinical trial studies the following conditions: B-cell Acute Lymphoblastic Leukemia (B-ALL).
What interventions are being tested in trial NCT07109219?
The interventions under investigation include: AZD4512 monotherapy (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT07109219?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07109219 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Iowa, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for B-cell Acute Lymphoblastic Leukemia (B-ALL)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
RECRUITING · Phase 1
-
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
RECRUITING · Phase 1
-
Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab
RECRUITING
-
Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)
RECRUITING · NA
-
CAR T-cell Long-Term Follow-Up, Quality of Life and Adverse Reactions
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02974647 · 83 participants · Phase 2
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
- NCT03919292 · 83 participants · Phase 1
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
- NCT04626674 · 83 participants · Phase 1
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
- NCT05277168 · 83 participants · Phase 1
A Trial TO Evaluate THE Safety, Tolerability, Pharmacokinetics, AND Efficacy OF Shr-a1904 IN Subjects With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI